Frontera Therapeutics’ Hong Kong IPO Application Lapses, Focused on Recombinant AAV Gene Therapy
NewTimeSpace News: Per information published on the official website of the Hong Kong Stock Exchange, the Main Board listing application filed by Frontera Therapeutics on 23 December 2025 has recently lapsed after the six-month validity period expired. UBS Group and Haitong International served as joint sponsors upon the initial filing.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Frontera Therapeutics files for HKEX listing; rAAV gene therapy company focused on ophthalmology and cardiovascular diseases with six candidates
- NewTimeSpace | "The First AAV Gene Therapy Stock", Frontera Therapeutics Files for Hong Kong IPO
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- Korean Stocks Open Higher but Close Lower as Semiconductor Heavyweights Slip; Csop Kospi 200 Etf (03121.HK) Falls 1.30%
- AOM INT'L (00381.HK): Launches Twelve Dynasties Wine Project Combining Cultural Export and Digital Assets
